Anti-Human CD20 (Rituximab) APC

IVMB0524

Product Information

Product SKU:	IVMB0524	**Clone**:	10F381	**Target**:	CD20
Size:	50 µg			**Isotype**:	Human IgG1κ

Additional Information

Reactivity:	Human/Rhesus Monkey/Cynomolgus Monkey	**Host Species**:	Human
Antibody Type:	Biosimilar Recombinant Human Monoclonal Antibody	**Expression Host**:	HEK-293 Cells

Immunogen Information

Background: CD20 is a 33-37 kD transmembrane-spanning phosphoprotein found on the surface of developing B-cells and various B-cell malignancies. CD20 is a popular target for mAb therapy because depleting developing B-cells generally does not cause permanent side effects (due to the fact that mature plasma cells and B-cell progenitors do not express CD20 and that there is limited expression of CD20 among other cell lineages). Rituximab is a chimeric monoclonal antibody that binds to CD20. The precise function of CD20 is still unknown. However, it is suspected to play a role in Ca2+ influx across plasma membranes, maintaining intracellular Ca2+ concentration, and allowing the activation of B cells. Rituximab is used to treat some autoimmune diseases and types of cancer such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis among others. The Fc portion of Rituximab mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Rituximab increases MHC II and adhesion molecules LFA-1 and LFA-3 (lymphocyte function-associated antigen) and also induces apoptosis of CD20+ cells. This ultimately results in the elimination of B cells (including the cancerous ones) from the body, and thus allows a new population of healthy B cells to develop from lymphoid stem cells. Anti-Human CD20 (Rituximab) utilizes the same variable regions from the therapeutic antibody Rituximab making it ideal for research projects.

Product Concentration: 0.2 mg/ml

Applications: FC

Contact Details | Dublin, Ireland
Email: techsupport@assaygenie.com | **Web:** www.assaygenie.com

Synonyms:	B1; S7; Bp35; CVID5; MS4A2; LEU-16; MS4A1; membrane spanning 4-domains A1
Antigen Distribution:	CD20 is primarily found on the surface of immune system B cells. CD20 is highly expressed in the lymph node, and to a lesser extent, the spleen and appendix.
Immunogen:	Human lymphoblastoid cell line SB.
Formulation:	This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Specificity:	This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Rituximab. Clone 10F381 recognizes human CD20. This product is for research use only.
Pathogen Testing:	-
Storage & Handling:	This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C.Do not freeze.

Contact Details | Dublin, Ireland
Email: techsupport@assaygenie.com | **Web:** www.assaygenie.com